Levi & Korsinsky notifies investors that it has commenced an investigation into Immutep Limited (NASDAQ: IMMP) concerning potential violations of the federal securities laws.
On January 30, 2026, Immutep filed a 6-K with the SEC stating that the TACTI-004 futility analysis was "on track for the first quarter of CY2026" and cited "strong operational progress" for the trial. The filing contained no reference to negative efficacy signals, enrollment difficulties, or data trends that might compromise the trial's primary endpoints. Six weeks later, on March 13, 2026, the IDMC announced the interim futility analysis showed the drug was unlikely to succeed and recommended stopping the study. TACTI-004 was Immutep's lead oncology asset. The January 30 filing framed the futility analysis as a forward milestone still approaching. The March 13 announcement revealed the analysis had concluded -- and the result was negative. The gap between the guidance and the outcome drove shares down as much as 90% in a single session.
If you suffered a loss on your Immutep Limited securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks.
We monitor critical case developments that may affect the price of your shares and your possible monetary recovery.
SnapTrade only shares the tickers you own and your transaction history — not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create an attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery — link your brokerage account with SnapTrade.